Jenette Bellitto, PhD is a Principal at BGBx Consulting, based in Washington, D.C. She joined BGBx from Kx Advisors and partners with clients ranging from emerging biotechs to global pharmaceutical leaders to unlock growth opportunities and guide high-impact portfolio and launch strategies. Jenette has deep expertise in voice-of-customer research, opportunity assessment, segmentation, market sizing, and new product strategy. She is known for bringing a rigorous, data-driven approach to navigating complex market dynamics and supporting confident decision-making across therapeutic areas including neuroscience, psychiatry, immunology, and medical aesthetics. Jenette holds a PhD in Biomedical Engineering from Yale University and a BS in Chemical Engineering from the University of California, Irvine.

Katie Devane is a Director at BGBx Consulting, where she partners with clients to solve complex, data-driven challenges across the healthcare and life sciences landscape. She brings a strong foundation in applying data to inform strategy and decision-making. Katie is known for her analytical approach and her ability to translate complex insights into clear, actionable direction. She also plays a key role in mentoring and developing teams, fostering collaboration, and challenging thinking to drive stronger outcomes.

Parrus Doshi is SVP, Global Brand Strategy at BGBx Consulting. He brings expertise across brand strategy, communications planning, and innovation, helping organizations translate complex market and behavioral insights into clear, actionable strategy. Parrus has partnered with global healthcare and consumer brands across a wide range of therapeutic and commercial categories, with a focus on shaping differentiated positioning, integrated communications, and behavior-changing campaigns. Prior to joining BGBx Consulting, Parrus held senior strategy leadership roles at McCann Health, where he led strategic planning initiatives across global healthcare brands and managed integrated strategy teams across EMEA. Earlier in his career, he also held strategy roles at TBWA\WorldHealth, Aesop Agency, and Brand and Deliver. Parrus holds a Bachelor’s Degree in Biomedical Science from King's College London.

Kimberly Dsilva is a Principal II at BGBx Consulting, based in New York City, with a background spanning product strategy, customer experience, AI, and technology innovation across healthcare and enterprise organizations. She has led the design and deployment of scalable digital products and AI-enabled experiences for startups through Fortune 50 companies, translating complex data, user behavior, and market insights into customer-centered solutions used by millions.
Prior to joining BGBx Consulting, Kimberly held consulting and product strategy roles at Slalom and Accenture, where she led the CX strategy team in NYC and multiple digital transformation initiatives across cross-functional teams and emerging technology ecosystems. She is known for bridging strategy and execution—helping organizations operationalize innovation through human-centered design, data-driven decision-making, and cutting-edge technologies.
Kimberly holds a BS in Computer and Information Technology from Purdue University and a Master’s degree in User Experience Design from the Maryland Institute College of Art.

Masha Dumanis is a Senior Vice President at BGBx Consulting, based in Boston. She joined Kx Advisors (now BGBx Consulting) in 2024 to co-lead the MedTech practice. Masha is a recognized advisor in the MedTech and Digital Health sectors, with particular expertise in musculoskeletal (MSK), urology/pelvic health, and women's health markets. Masha brings 15 years of experience in healthcare strategy consulting, where she has supported clients across growth strategy, go-to-market planning, commercial due diligence, market access, M&A, and corporate strategy. She is known for building strong client partnerships and guiding data-driven decision-making in complex and evolving markets. Masha previously held leadership roles at Health Advances, where she led the MSK practice area. She holds an A.B. cum laude in Human Evolutionary Biology from Harvard College and serves as a Senior Advisor to the Journal of Orthopaedic Experience & Innovation (JOEI).

Anna Gaudio is SVP, CX Innovation at BGBx Consulting. She brings experience advising across customer experience, digital strategy, commercial strategy, and innovation, helping healthcare and life sciences organizations create more meaningful, engaging brand experiences that shape better health outcomes. Anna is known for practical integration of design thinking, behavioral insights, and emerging technologies to shape customer engagement strategies that drive growth, differentiation, and long-term brand value. Prior to joining BGBx Consulting, Anna held senior strategy and innovation leadership roles at McCann Health, Sera Prognostics, and ghg, greyhealth group, where she led customer experience, omnichannel engagement, and innovation initiatives across healthcare brands and therapeutic areas. She also serves as an Adjunct Professor at Utah Valley University, teaching experience mapping and communications planning at the MBA level. Anna holds a Master of Science in Marketing from Liberty University and a BS in Communication Studies from Liberty University.

Hilary Gentile is Chief of Commercial Strategy and Innovation at BGBx, where she leads the organization’s strategy and innovation efforts, overseeing the roadmap for BGBx’s AI-enabled technology suite and helping clients navigate increasingly complex commercial challenges. She focuses on integrating data, behavioral science, and emerging technologies to drive measurable business impact and more adaptive decision-making across the healthcare landscape.

With more than two decades of experience across healthcare and life sciences, Hilary brings deep expertise in commercial strategy, portfolio planning, organizational transformation, and innovation. She has led high-stakes launches, guided portfolio strategy, and supported transformation initiatives tied to mergers, acquisitions, and evolving commercial models. Hilary is recognized for helping organizations move beyond static planning toward more insight-driven, adaptive approaches to commercialization and has been featured at industry forums including the PM360 SPARK Transformation Summit. Hilary holds a bachelor's degree from Smith College, and an executive MBA from the NYU School of Business.

David Geschwind is a Vice President at BGBx Consulting, based in San Francisco. He brings extensive experience leading growth strategy engagements for pharmaceutical, biotechnology, MedTech, and digital health companies, with a focus on product launch strategy, commercial operations, financial modeling and forecasting, commercial due diligence, pricing, and market access. David's previous experience includes roles at Kx Advisors, where he advised clients across therapeutic areas including interventional medicine, medical aesthetics, eye care, dermatology, and oncology. He is known for translating complex market and financial dynamics into clear, actionable strategy. David holds a B.A. in Computer Science and Economics from Swarthmore College.

Marc Geschwind is a Principal at BGBx Consulting, based in Chapel Hill, North Carolina. He brings extensive experience leading growth strategy engagements across medical aesthetics, pharmaceutical, MedTech, and animal health sectors, advising clients on brand and franchise planning, commercial operations, product and portfolio strategy, and commercial due diligence. In previous roles, Marc developed particular expertise in medical aesthetics, supporting engagements across injectables, skincare, and energy-based devices. His broader therapeutic experience spans cardiovascular disease, neurology, orthopedics, inflammatory diseases, and plastic and regenerative medicine. Marc holds a B.A. in Economics from Swarthmore College.

Steve Goldstein is EVP, Marketing and Product Development at BGBx Consulting. His experience spans more than 25 years across pharmaceutical commercialization, brand strategy, and product launch planning, helping healthcare organizations navigate complex commercial and market access challenges across multiple therapeutic areas. Steve has deep expertise across immunology, oncology, neurology, and gastroenterology, with experience leading HCP and DTC strategy for major brand launches and lifecycle planning initiatives across global and US markets. Prior to joining BGBx Consulting, Steve held senior commercial leadership roles at Bristol Myers Squibb and Novartis, where he led launch, lifecycle management, and consumer marketing initiatives across numerous portfolios. Steve holds a BSBA in Finance and International Business from Washington University in St. Louis.

Katie Harris is a Principal at BGBx Consulting, where she partners closely with clients to deliver strategic, creative solutions that drive meaningful results across the life sciences landscape. She brings a collaborative, client-focused approach to solving complex challenges and advancing growth strategies. Katie is known for leading high-performing teams, fostering strong partnerships, and bringing clarity and energy to every engagement while helping develop the next generation of talent.

Tess Huffstater is a Principal at BGBx, based in Boston. She partners with biopharmaceutical and biotechnology clients to shape growth strategies across oncology, immunology, and rare diseases, with a focus on early asset and portfolio strategy, market shaping, and commercial readiness planning. In previous roles, Tess helped teams define clear value propositions, align cross-functional stakeholders, and prepare for successful launches, with additional experience in market access strategy. With a background that bridges science and strategy, she is known for bringing structure and clarity to complex decisions in drug development. Tess holds a B.S. and M.Eng. in Biomedical Engineering from Cornell University and a Ph.D. in Biomedical Engineering from Vanderbilt University, where her research focused on novel drug targets for kidney disease.

Sonya Jakawich is a Senior Vice President at BGBx Consulting, based in New York City. She brings more than 13 years of experience in life sciences strategic advisory, partnering with organizations across the healthcare ecosystem to shape early product and portfolio strategies. Sonya has advised global pharmaceutical companies, emerging biotechs, and investment firms on strategic decision-making across therapeutic areas including oncology, obesity/T2D, and immunology. She previously held roles at Kx Advisors, Pfizer, and Trinity Life Sciences, developing a strong foundation in both scientific and commercial strategy. She holds a Ph.D. in Neuroscience from the University of Michigan and a B.S. in Cellular and Molecular Biology from the University of Washington.

Jenny Knauss is a Vice President at BGBx Consulting with nearly a decade of experience across healthcare consulting and communications. She brings deep expertise in oncology, spanning both solid tumors and hematologic malignancies, and applies principles of strategy and development in complex disease states across therapeutic areas. Jenny leads the Medical and Evidence Strategy practice area at BGBx, where she partners with Medical Affairs and Commercial teams to inform strategy from early clinical development, landscape analysis, and evidence generation through launch planning, brand strategy, and lifecycle management. Jenny joined BGBx from Kx Advisors and previously held roles at BGB Group and McKinsey & Company, giving her a unique perspective across strategy and execution. She holds a PhD in Cell and Developmental Biology from Weill Cornell Medicine Graduate School of Medical Sciences and a BS in Biology from American University.

Kalynn Kresge is EVP at BGBx Consulting, based in the New York City metropolitan area. She brings specialized expertise at the intersection of strategy, innovation, data, and technology—helping healthcare and life sciences organizations translate complex market, customer, and performance data into actionable commercial growth strategies. Kalynn is known for connecting insight, advanced analytics, and behavioral understanding to shape differentiated go to market strategu, accelerate decision-making, and drive measurable business impact. Prior to joining BGBx Consulting, Kalynn held senior leadership roles at Innovation x Intelligence, 90North, an IPG Health Company, and McCann Health, where she led strategic planning and innovation initiatives across a broad range of healthcare brands and therapeutic areas. She holds a BA in Biology, with minors in Business and Psychology, from Lehigh University.

Nikil Kumar is a Partner at BGBx Consulting, based in New York. He brings extensive experience partnering with pharmaceutical and biotech organizations to develop pragmatic, growth-focused strategies, with particular depth in oncology across both solid and hematologic malignancies. Nikil has led engagements spanning market opportunity assessment, portfolio strategy, product launch planning, and marketing strategy. He has held strategy consulting roles at Kx Advisors and Omnicom Health Group, giving him a strong foundation in translating strategy into effective market execution. He holds a B.S. in Neuroscience from Stony Brook University.

Sean Vander Linde is a Partner at BGBx Consulting, based in Washington, DC. He brings deep experience advising organizations across the healthcare value chain, including providers, health IT, biopharma, and medical device companies. With extensive experience leading engagements focused on corporate strategy, market opportunity assessment, product launch planning, and commercial due diligence, Sean's work is centered on helping clients navigate complex market dynamics and translate strategic insight into actionable growth plans. Sean previously held roles at Kx Advisors, L.E.K. Consulting, and PwC, where he focused on healthcare strategy and transformation. Sean holds an MBA from the Tuck School of Business at Dartmouth and a BA in Political Science from the University of North Carolina at Chapel Hill.

Chloe Lok is a Vice President at BGBx Consulting, based in London. She brings over 10 years of experience in the healthcare industry, leading engagements across pharmaceutical, biotechnology, and digital health organizations. She joined BGBx from Kx Advisors and brings deep expertise in rare diseases, immunology, and hematology, with additional experience spanning respiratory and psychiatry. Chloe partners with global clients to shape asset and portfolio strategy, guide launch planning, and navigate complex commercial and clinical landscapes. She is known for her ability to integrate qualitative and quantitative insights into clear, actionable strategy, with strengths in strategic marketing, patient journey mapping, and forecasting. Chloe holds an MSc in Management from Imperial College Business School and a BSc in Biochemistry from the University of Reading.

Dave MacDougall is a Managing Director and Co-Founder at BGBx Consulting. He joined BGBx from Hayden Consulting Group, which he co-founded, and brings a deep background in business and market access to solve complex client needs and unlock growth opportunities. Dave is known for helping clients integrate market access into overall commercialization strategy, with a focus on the intersection of data-driven decision-making and strategic insight. In addition to working closely with clients, he plays a key role in evolving capabilities, processes, and culture to support continued growth.

Bryan McDonald is a Principal at BGBx Consulting, where he partners with clients to shape commercial strategy with a focus on leveraging data to inform market access approaches and optimize opportunities for new product launches. He brings a strong foundation in translating complex data into actionable access and commercialization strategies. Bryan is also passionate about mentoring and coaching team members, supporting both formal development and on-the-job growth.

Dan O’Neill is a Managing Partner at BGBx Consulting. He is based in Washington, DC. Dan has significant experience developing commercial growth strategies for leading pharmaceutical, medical device, and health technology clients. Dan has spent nearly two decades advising leading life sciences organizations on high-stakes strategic decisions. With extensive experience across therapeutic areas and project types, and a focus on commercial due diligence, strategic marketing, product launch planning, market opportunity assessment, and competitive strategy, Dan has expertise in integrated research and quantitative modeling techniques related to product pricing and forecasting. Dan started his career in finance and banking, where he developed his quantitative background. Dan holds an MBA from the McDonough School of Business at Georgetown University and a BBA from the University of Kentucky.

Andy Pollpeter is a Director at BGBx Consulting, where he partners with clients to navigate the evolving landscape of U.S. market access and reimbursement. He brings deep experience leveraging real-world data to inform commercial decision-making and access strategy. Andy is known as a highly engaged project leader, coach, and mentor who challenges teams to think creatively and strategically while delivering clear, actionable insights.

Bob Serrano is a Managing Partner at BGBx Consulting, based in Washington, DC. He brings nearly two decades of experience across the healthcare industry, with a focus on developing growth strategies for specialty pharmaceutical, interventional medicine, and clinical diagnostics organizations. Bob has advised leading life sciences companies on strategic growth, market development, and commercial execution. His work spans a wide range of therapeutic areas, including oncology, dermatology, neurology, immunology, and cardiology, with a consistent focus on translating complex market dynamics into clear, actionable strategy. Bob has held strategy and sales roles at Kx Advisors and Abbott Laboratories (now AbbVie), where he gained firsthand experience in commercial operations. He also led North American laboratory marketing for QIAGEN’s molecular diagnostics business, bringing a deep understanding of how strategy translates into execution in highly technical and regulated markets. Bob holds an MBA from the Kellogg School of Management at Northwestern University, as well as a Master’s in Health Administration and a BS in Nutritional Science from Cornell University.

Jamie Sidore is a Managing Director at BGBx Consulting, bringing deep expertise at the intersection of commercial strategy and market access. He joined BGBx from Hayden Consulting Group, which he co-founded to help life sciences organizations integrate access considerations into broader commercialization strategy. Jamie is known for building high-impact client partnerships, developing new capabilities, and shaping teams that can navigate complex market dynamics with clarity and confidence.

Max Tabb is a Senior Principal at BGBx Consulting, where he helps clients understand how market access dynamics shape brand, portfolio, and corporate strategy. He is a core contributor to thought leadership and plays a key role in advancing learning and development programs. Max brings a strategic, access-informed lens to complex decisions, helping teams connect market dynamics to actionable commercial strategy.

Mudita Vaish is a Partner at BGBx Consulting, based in London. She joined Kx Advisors (now BGBx Consulting) in 2025 and leads the London office. She brings more than 15 years of consulting experience focussed in the healthcare and life sciences industry, with deep expertise in commercial launch strategy, data-driven brand planning, and AI-enabled insights. Mudita has advised leading global pharmaceutical companies on market entry, brand planning, launch execution and asset performance tracking, across therapeutic areas including oncology, immunology, ophthalmology, neurology, and rare diseases. She has also held life sciences and healthcare commercial strategy roles at IQVIA and PwC Strategy&, helping clients shape data-driven strategies across EMEA. Mudita holds an MSc in Management and Strategy from the London School of Economics and Political Science, an MSc in Economics from Indira Gandhi Institute of Development Research, and a BA in Economics from the University of Delhi.

Chris Waybill is a Senior Vice President at BGBx Consulting, based in the San Francisco Bay Area. He brings more than a decade of experience in strategy consulting, leading growth strategy engagements across corporate strategy, business development and M&A, product development, and commercial go-to-market planning, with particular emphasis on brand planning and launch strategy. Chris has extensive experience advising leading pharmaceutical, biotechnology, and medical device companies across therapeutic areas including CNS, dermatology, and immunology, as well as interventional technologies, diagnostics, and connected devices. He is known for his expertise in complex CNS conditions—spanning cognitive disorders, neuropsychiatric diseases, pain, movement disorders, and cerebrovascular conditions—and for helping clients apply advanced analytics, behavioral science, and AI-driven approaches to sharpen strategic decision-making. Chris holds a B.S.E. in Mechanical Engineering and Materials Science from Duke University.